Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025


The board of directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has today resolved on a directed issue of convertibles to Fenja Capital II A/S (“Fenja”) raising gross proceeds of SEK 12 million (the “Convertibles”). Furthermore, the Company has also entered into an agreement with Fenja for a loan facility of up to SEK 68 million (the “Loan Facility” and together with the Convertibles, the “Financing”). The transaction provides Alligator with financial and strategic flexibility, with the full Financing extending the cash runway into the first quarter of 2025.
Reasons and motives for the Financing
The Financing consists of a first tranche of SEK 50 million, of which SEK 12 million are Convertibles and SEK 38 million is a loan under the Loan Facility, and a second tranche for the remaining SEK 30 million as a loan under the Loan Facility. This second tranche is available provided that the total Financing does not exceed 10.00 percent of the Company’s market capitalization at the time the second tranche is drawn. The Convertibles entail a potential maximum dilution of the current number of ordinary shares of approximately 1.07 percent. The Financing shall be repaid at the latest on March 25, 2025.
With the currently available cash and the full SEK 80 million Financing, Alligator has a cash runway into the first quarter of 2025, covering the finalization of the OPTIMIZE-1 study, the continued Phase 3 preparation for mitazalimab in first-line metastatic pancreatic cancer, and the continued development of its earlier stage immuno-oncology pipeline.

Alligator is heading toward several potentially transformative value inflection points during the next six to 12 months, primarily driven by the outstanding clinical performance of our lead asset mitazalimab in the OPTIMIZE-1 Phase 2 trial. This liquidity injection provides Alligator with time and maneuverability, placing us in a position of strength in the ongoing business development process to secure the right commercial partner to progress mitazalimab into Phase 3 development and on to market, and to deliver the best possible deal for the Company and our shareholders.” says Søren Bregenholt, CEO of Alligator.

Terms of the Convertibles
The board of directors has today, pursuant to the authorization granted by the annual general meeting on May 7, 2024, resolved on a directed issue of convertibles. The aggregate nominal value of the Convertibles amounts to SEK 12 million. Fenja has the right to request conversion of the Convertibles into ordinary shares at a conversion price of SEK 1.47 per share, which corresponds to 125 percent of the volume weighted average price for the Company’s shares during the period of ten trading days up to and including June 24, 2024. Conversion can be requested as from the date of registration of the Convertibles with the Swedish Companies Registration Office up to and including March 25, 2025, and any request for conversion has to be for an amount of at least SEK 4 million.
The Convertibles accrue interest at an annual rate of STIBOR 3M (fixed as of the date of disbursement of the Convertibles) plus 10.00 percent. The interest is due for payment at the final maturity date of the Convertibles. Unless previously converted, the Convertibles shall be repaid at the latest on March 25, 2025.
Terms of the Loan Facility
The Loan Facility entered into with Fenja amounts to a total of up to SEK 68 million, divided into two tranches of SEK 38 million and SEK 30 million respectively. The first tranche is disbursed in connection with the signing of the Loan Facility and the second tranche can be drawn by the Company from the date of the signing of the Loan Facility and up until September 25, 2024, at the latest. The Company’s right to draw the second tranche is conditional upon the total amount outstanding under the Convertibles plus the Loan Facility (after disbursement of the second tranche) does not exceed 10.00 percent of the Company’s market capitalization at the time of the draw down request. The loans drawn under the Loan Facility accrue interest at an annual rate of STIBOR 3M (for both tranches, fixed as of the disbursement of the first tranche) plus 10.00 percent. Until the second tranche is disbursed or cancelled, an interest corresponding to STIBOR 3M accrues on the undisbursed second tranche. The loans mature on March 25, 2025, and the interest is due for payment at the final maturity date. To the extent the Company would execute new issues of shares while the Convertibles and loans under the Loan Facility are outstanding, the Company shall, with certain exemptions, use the net-proceeds from such new issues to repay the outstanding amounts under the Convertibles and the Loan Facility.
In connection with the Financing, the Company will pay an arrangement fee to Fenja of SEK 4 million, which will be deducted from the first tranche under the Loan Facility.
Reasons for deviation from the shareholders’ preferential rights etc.
The issue of the Convertibles constitutes and integrated part of the Financing. The purpose of the Financing and the reason for the deviation from the shareholders’ preferential rights in relation to the issue of the Convertibles is the need for ongoing working capital as well as enabling the Company to finalize the OPTIMIZE-1 study, continue Phase 3 preparation for mitazalimab in first-line metastatic pancreatic cancer, and continue development of the Company’s earlier stage immuno-oncology pipeline. The Company has weighed the advantages and disadvantages of a rights issue and concluded that a rights issue (i) would be significantly more time-consuming, which may risk that the Company misses out on potential growth opportunities, (ii) would lead to significantly higher costs for the Company, mainly attributable to the procurement of an underwriting consortium and legal costs, (iii) would expose the Company to higher market volatility, especially given the current market conditions, and (iv) would most likely have to be carried out at a lower issue price and result in a higher dilution, which would have been to the detriment of all shareholders. Furthermore, the Convertibles contribute to improving the Company’s capital structure and risk level by providing the Company with financing with increased flexibility compared to a customary new issue of shares.
In this respect, the board of directors has particularly considered the importance of being able to carry out the raising of capital in a way that ensures that the Company obtains sufficient working capital at a proportionate cost.
In view of the above and after careful consideration, it is the board of directors’ assessment that the Financing is the most favorable financing alternative for the Company, and in the interest of both the shareholders and the Company, and therefore also justifies a deviation from the main rule of the shareholders’ preferential rights.
The conversion price as well as the other terms for the Financing has been established through a negotiation at arm’s length between the Company and Fenja. In connection herewith, the board of directors has taken into account general market conditions to raise capital, whereby the terms and conditions for the Financing in an overall assessment are deemed to be in accordance with market conditions.
Share capital, shares and dilution
Provided that all Convertibles are converted into shares, the share capital will increase with SEK 6,530.6120 from SEK 607,191.2688 to SEK 613,721.8808 through the issue of 8,163,265 ordinary shares, resulting in that the total number of shares increases from 758,989,086 to 767,152,351, whereof 766,202,501 are ordinary shares and 949,850 are series C shares. Thus, the Convertibles entails a potential maximum dilution of the ordinary shares of approximately 1.07 percent.

Setterwalls Advokatbyrå AB acts as legal advisor to the Company in connection with the Financing.

Updated 2024-06-25